Myriad Genetics, Inc. – LSE:0K3W.L

Myriad Genetics stock price today

$29.88
+16.5
+123.32%
Financial Health
0
1
2
3
4
5
6
7
8
9

Myriad Genetics stock price monthly change

-48.91%
month

Myriad Genetics stock price quarterly change

-48.91%
quarter

Myriad Genetics stock price yearly change

-33.30%
year

Myriad Genetics key metrics

Market Cap
 1.20B
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -3.36
Revenue
 734.4M
EBITDA
 -212.4M
Income
 -274.4M
Revenue Q/Q
 22.69%
Revenue Y/Y
 11.03%
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 -28.92%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Myriad Genetics stock price history

Myriad Genetics stock forecast

Myriad Genetics financial statements

Profit Margin

Myriad Genetics, Inc. (LSE:0K3W.L): Profit margin
Dec 2022 177.8M -42.3M -23.79%
Mar 2023 181.2M -54.7M -30.19%
Jun 2023 183.5M -116.1M -63.27%
Sep 2023 191.9M -61.3M -31.94%
0K3W.L income statement history

Myriad Genetics Financials Estimate

Myriad Genetics, Inc. (LSE:0K3W.L): Analyst Estimates
Sep 2025 227.64M 7.31M 3.21%
Oct 2025 223.43M 4.21M 1.89%
Dec 2025 236.84M 10.82M 4.57%
Dec 2025 235.26M 8.42M 3.58%

  • Analysts Price target

  • Financials & Ratios estimates

Show more
0%
Yield TTM
Myriad Genetics, Inc. (LSE:0K3W.L): Payout ratio
Payout ratio 0%
Myriad Genetics, Inc. (LSE:0K3W.L): Dividend Yield
2020 40.79%
2020
2021
2022
2023
0K3W.L dividends history

Debt to Assets

Myriad Genetics, Inc. (LSE:0K3W.L): Debt to assets
Dec 2022 1198700000 312.9M 26.1%
Mar 2023 1169300000 334.1M 28.57%
Jun 2023 1187200000 452M 38.07%
Sep 2023 1149100000 465.7M 40.53%
0K3W.L balance sheet history

Cash Flow

Myriad Genetics, Inc. (LSE:0K3W.L): Cash Flow
Dec 2022 -7.7M -35.6M -2.1M
Mar 2023 -33.2M 34.6M -4.9M
Jun 2023 -900K 11.8M 38.4M
Sep 2023 -22.1M -2.5M -2.5M
0K3W.L cash flow history

Myriad Genetics alternative data

Myriad Genetics
Employees

Myriad Genetics, Inc. (LSE:0K3W.L): Employee count
Aug 2023 2,600
Sep 2023 2,600
Oct 2023 2,600
Nov 2023 2,600
Dec 2023 2,600
Jan 2024 2,600
Feb 2024 2,600
Apr 2024 2,700
May 2024 2,700
Jun 2024 2,700
Jul 2024 2,700

Myriad Genetics other data

Myriad Genetics
Patents

Patent
Application
Filling date: 23 Feb 2022 Issue date: 18 Aug 2022
Application
Filling date: 13 Jan 2022 Issue date: 4 Aug 2022
Application
Filling date: 8 Dec 2021 Issue date: 30 Jun 2022
Application
Filling date: 12 Oct 2021 Issue date: 30 Jun 2022
Application
Filling date: 4 Oct 2021 Issue date: 30 Jun 2022
Application
Filling date: 24 Sep 2021 Issue date: 14 Apr 2022
Grant
Filling date: 21 Nov 2019 Issue date: 16 Nov 2021
Grant
Filling date: 11 Nov 2016 Issue date: 16 Nov 2021
Application
Filling date: 22 Jul 2021 Issue date: 11 Nov 2021
Application
Filling date: 21 Jun 2021 Issue date: 7 Oct 2021
0K3W.L patents

Myriad Genetics
Executives

Insider Compensation
Mr. R. Bryan Riggsbee (1971) Executive Vice President, Chief Financial Officer & Treasurer
 $741,840
Dr. Jerry S. Lanchbury (1959) Chief Scientific Officer $632,040
Ms. Nicole Lambert (1975) Group Pres of Myriad Oncology, Myriad Women's Health & Myriad International $507,510
Mr. Benjamin Jackson Executive Vice President, Gen. Counsel & Sec.
Ms. Jayne Baird Hart Executive Vice President of HR
Dr. Clivetty Martinez Chief Compliance Officer
Mr. Scott Gleason Senior Vice President of Investor Relations
Mr. Mark S. Verratti Pres of Myriad Neuroscience & Myriad Autoimmune
Mr. Paul Chip Parkinson Executive Vice President of Reimbursement Strategy
Mr. Paul J. Diaz Chief Executive Officer, Pres & Director

Frequently Asked Questions (FAQ)

  • What's the price of Myriad Genetics stock today?

    One share of Myriad Genetics stock can currently be purchased for approximately $29.88.

  • When is Myriad Genetics's next earnings date?

    Unfortunately, Myriad Genetics's (0K3W.L) next earnings date is currently unknown.

  • Does Myriad Genetics pay dividends?

    No, Myriad Genetics does not pay dividends.

  • How much money does Myriad Genetics make?

    Myriad Genetics has a market capitalization of 1.20B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 11.03% to 753.2M US dollars.

  • What is Myriad Genetics's stock symbol?

    Myriad Genetics, Inc. is traded on the LSE under the ticker symbol "0K3W.L".

  • What is Myriad Genetics's primary industry?

    Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.

  • How do i buy shares of Myriad Genetics?

    Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Myriad Genetics's key executives?

    Myriad Genetics's management team includes the following people:

    • Mr. R. Bryan Riggsbee Executive Vice President, Chief Financial Officer & Treasurer(age: 54, pay: $741,840)
    • Dr. Jerry S. Lanchbury Chief Scientific Officer(age: 66, pay: $632,040)
    • Ms. Nicole Lambert Group Pres of Myriad Oncology, Myriad Women's Health & Myriad International(age: 50, pay: $507,510)
    • Mr. Benjamin Jackson Executive Vice President, Gen. Counsel & Sec.
    • Ms. Jayne Baird Hart Executive Vice President of HR
    • Dr. Clivetty Martinez Chief Compliance Officer
    • Mr. Scott Gleason Senior Vice President of Investor Relations
    • Mr. Mark S. Verratti Pres of Myriad Neuroscience & Myriad Autoimmune
    • Mr. Paul Chip Parkinson Executive Vice President of Reimbursement Strategy
    • Mr. Paul J. Diaz Chief Executive Officer, Pres & Director

  • How many employees does Myriad Genetics have?

    As Jul 2024, Myriad Genetics employs 2,700 workers.

  • When Myriad Genetics went public?

    Myriad Genetics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.

  • What is Myriad Genetics's official website?

    The official website for Myriad Genetics is myriad.com.

  • Where are Myriad Genetics's headquarters?

    Myriad Genetics is headquartered at 320 Wakara Way, Salt Lake City, UT.

  • How can i contact Myriad Genetics?

    Myriad Genetics's mailing address is 320 Wakara Way, Salt Lake City, UT and company can be reached via phone at 801 584 3600.

Myriad Genetics company profile:

Myriad Genetics, Inc.

myriad.com
Exchange:

LSE

Full time employees:

2,700

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

801 584 3600
320 Wakara Way
Salt Lake City, UT 84108

:
ISIN: US62855J1043
: